SCHEMBL2329971

SCHEMBL2329971

O=C(Cl)c1cccnc1Oc1cc(Cl)ccc1Cl

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 12/20 0.60
CYP2C9 P11712 3/20 0.53
CYP3A4 P08684 2/20 0.53
RAB9A P51151 1/20 0.51
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C19 P33261 2/20 0.46
GAA P10253 2/20 0.44
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
MEN1 O00255 1/20 0.43
PKM P14618 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749510 0.90 HTR1A (0.51) GPBAR1CYP2C9CYP3A4RAB9ACYP1A2
SCHEMBL29209321 0.90 HTR1A (0.51) GPBAR1CYP2C9CYP3A4RAB9ACYP1A2
SCHEMBL2335696 0.89 GPBAR1 (0.60) GPBAR1CYP2C9CYP3A4RAB9ACYP1A2
SCHEMBL28117572 0.81 GPBAR1 (0.57) GPBAR1CYP2C9CYP3A4CYP1A2CYP2D6
SCHEMBL3141314 0.81 GPBAR1 (0.60) GPBAR1CYP2C9CYP3A4RAB9ACYP1A2
SCHEMBL2924686 0.81 RAB9A (0.76) RAB9AGAAALDH1A1POLBTDP1
SCHEMBL3137865 0.81 GPBAR1 (0.63) GPBAR1CYP2C9CYP3A4RAB9ACYP1A2
SCHEMBL7674124 0.80 ALDH1A1 (0.58) CYP2C9RAB9ACYP1A2CYP2C19GAA
SCHEMBL3137908 0.80 GPBAR1 (0.72) GPBAR1CYP2C9CYP3A4RAB9AALDH1A1
SCHEMBL3142853 0.80 GPBAR1 (0.54) GPBAR1CYP2C9CYP3A4RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309734-B2 Substituted pyridines as GPBAR1 agonists HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2356094-A1 NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS F. Hoffmann-La Roche AG (CH) 2011-08-17 EP disclosed
WO-2010049302-A1 NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO disclosed
US-20100105906-A1 NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105906-A1 NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES GPBAR1, GPR119, GLP1R GPBAR1 1/4885CYP2C9 1256/4885CYP3A4 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.